Aphria delivers 1,500 bottles of Rideau oil to
its subsidiary ABP to support the advancement of clinical medical
cannabis research
The Company also completes first shipment of
medical cannabis to Malta-based
subsidiary ASG Pharma
LEAMINGTON, ON, Oct. 15, 2018 /CNW/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APH and
US OTC: APHQF) today announced that it has completed its
first shipment of cannabis oil to its Argentina-based subsidiary ABP, S.A.
("ABP" or the "Argentinean Company"), a
pharmaceutical import and distribution company. In accordance with
a previously announced supply agreement, the Company delivered
1,500 bottles of Aphria's renowned Rideau CBD oil, which were
provided to Hospital de Pediatria Garrahan ("Hospital
Garrahan" or the "Hospital"), a leading pediatric
hospital located in Buenos Aires,
for use in a clinical study focused on treating refractory epilepsy
in children.
![Aphria Logo (CNW Group/Aphria Inc.) Aphria Logo (CNW Group/Aphria Inc.)](https://mma.prnewswire.com/media/767941/Aphria_Inc__Aphria_completes_first_shipment_of_cannabis_oil_to_A.jpg)
Aphria acquired ABP last month when the Company closed its
acquisition of LATAM Holdings Inc. ("LATAM Holdings"),
expanding the Company's global footprint to include a leading
presence in Latin America and the
Caribbean. "Argentina will play a foundational role as
Aphria cements its leadership in medical cannabis throughout the
region," said Vic Neufeld, Chief
Executive Officer of Aphria. "Aphria and ABP, in close partnership
with the Argentinean government, continue to advance opportunities
for medical cannabis in the country, including the potential for
in-country cultivation. We are also proud to support the critical
and necessary research being undertaken by Hospital Garrahan on the
treatment of refractory epilepsy in children with our Rideau CBD
oil."
As a well-established and successful pharmaceutical import and
distribution company, ABP was granted the first permit issued by
the Argentina Ministry of Health for the import of
pharmaceutical-grade medical cannabis. The Argentinean Company has
been forging a reputation as a champion for the research and
clinical study of medical cannabis, including through its
partnership with the Hospital, one of the most recognized and
credible medical institutions in South
America.
The clinical study, which involves 100 patients and will be
conducted over 2.5 years, will be one of the foundational global
scientific and medical studies of its kind focused on treating
refractory epilepsy in children. Medical researchers will conduct a
pharmacokinetics study of the Rideau product, which will help
optimize the ideal dosage in future patients. Top neurologists and
pediatric specialists from around the country will participate and,
with the support of ABP and Aphria, will receive training and
support to be able to train and educate a network of doctors
throughout Argentina.
Aphria completes first shipment of medical cannabis to ASG
Pharma
The Company also announced it has completed its first shipment
of cannabis oil to its Malta-based
subsidiary ASG Pharma Ltd. ("ASG"). The majority-owned
subsidiary received the first import certificate for medical
cannabis issued by the Government of Malta's Ministry of Health and will use this
first delivery of Aphria's renowned Rideau CBD oil to perform
analytical testing and research.
"This marks another important milestone as we continue to
execute on our strategic expansion plans in Europe and around the world," added Neufeld.
"Our EU-GMP certified lab in Malta
will play an important role for the Company in accessing cannabis
markets across the continent, and it will stand as a leading
European centre for the research and testing of medical cannabis
and derivative products."
ASG's facilities, which are undergoing a multi-million-euro
upgrade of its processing and manufacturing capabilities, will
serve as Aphria's hub for importing cannabis resin and dried flower
for processing, packaging and distribution of EU-GMP certified
cannabis products throughout large parts of Europe
We Have A Good Thing Growing
About Aphria
Aphria is a leading global cannabis company driven by an
unrelenting commitment to our people, product quality and
innovation. Headquartered in Leamington,
Ontario – the greenhouse capital of Canada – Aphria has been setting the standard
for the low-cost production of safe, clean and pure
pharmaceutical-grade cannabis at scale, grown in the most natural
conditions possible. Focusing on untapped opportunities and backed
by the latest technologies, Aphria is committed to bringing
breakthrough innovation to the global cannabis market. The
Company's portfolio of brands is grounded in expertly-researched
consumer insights designed to meet the needs of every consumer
segment. Rooted in our founders' multi-generational expertise in
commercial agriculture, Aphria drives sustainable long-term
shareholder value through a diversified approach to innovation,
strategic partnerships and global expansion, with a presence in
more than 10 countries across 5 continents.
For more information, visit: aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to the success and outcome
of the clinical trial, expected demand or need for the product by
participants or other patients following the clinical trial, the
ability to use the study data and results in support of product
registrations and product approvals and future product approvals,
internal expectations, estimated margins, expectations with respect
to actual production volumes, expectations for future growing
capacity and costs, the completion of any capital project or
expansions, and expectations with respect to future production
costs. Forward-looking statements necessarily involve known and
unknown risks, including, without limitation, risks associated with
general economic conditions; adverse industry events; marketing
costs; loss of markets; future legislative and regulatory
developments involving medical marijuana; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
medical marijuana industry in Canada generally, income tax and regulatory
matters; the ability of Aphria to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.